Paddy Koen Camiel Janssen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paddy Koen Camiel Janssen has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Frank de Vries
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, the Netherlands
9 shared publications Berend Olivier
Neurobiology, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands
8 shared publications- Andrea Michelle Burden
Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
7 shared publications - Joost Johan Van Raaij
Department of Clinical Pharmacy and Toxicology, VieCuri Medical Center , Venlo, 5912 BL
6 shared publications Marcel D. Waldinger
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA
6 shared publications- Sander de Kort
Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
6 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
Mass Spectrometric Characterization of Flucloxacillin Binding to Serum Albumin in Hospitalized Patients With Hypoalbuminemia: An Observational Pilot Study
Purpose: To facilitate antibiotic dose optimization, novel insights into flucloxacillin pharmacokinetics and serum protein binding in critically ill patients are needed. Therefore, this study assessed the number of flucloxacillin molecules bound to a serum albumin molecule (stoichiometry) in hospitalized patients with hypoalbuminemia. Methods: Adult hospitalized patients with serum hypoalbuminemia administered intravenous flucloxacillin were enrolled in this prospective, observational, single-center pilot study. Patients treated with piperacillin/tazobactam or amoxicillin/clavulanic acid served as controls. Matrix-assisted laser desorption–ionization time-of-flight mass spectrometry measurements were performed to calculate the stoichiometry of the antibiotic/albumin complexes. In addition, the associations between the stoichiometry and antibiotic treatment duration, serum albumin concentration, or time since flucloxacillin treatment cessation were assessed using association plots. Results: Eleven patients treated with flucloxacillin and 4 control patients were enrolled. A total of 251 stoichiometric measurements were considered. Large intra- and interindividual differences were observed in the stoichiometry. These values ranged from 0 to 6 flucloxacillin molecules bound to albumin. In 8 patients (72%), an increase in the stoichiometry as the number of flucloxacillin treatment days increased was confirmed. In addition, the stoichiometry increased at low albumin concentrations, and a stoichiometry of ≥3 was observed for 2–8 days after flucloxacillin treatment cessation. Conclusions: Prolonged flucloxacillin treatment and low serum albumin concentrations were associated with a high stoichiometry of flucloxacillin/albumin complexes in hospitalized patients with serum hypoalbuminemia. This study illustrates that protein binding is not a constant, thereby contributing to current understanding of the pharmacokinetics, effectiveness, and toxicity of flucloxacillin.
- 8 July 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
Open AccessMass Spectrometric Characterization of Flucloxacillin Binding to Serum Albumin in Hospitalized Patients With Hypoalbuminemia: An Observational Pilot Study
Purpose: To facilitate antibiotic dose optimization, novel insights into flucloxacillin pharmacokinetics and serum protein binding in critically ill patients are needed. Therefore, this study assessed the number of flucloxacillin molecules bound to a serum albumin molecule (stoichiometry) in hospitalized patients with hypoalbuminemia. Methods: Adult hospitalized patients with serum hypoalbuminemia administered intravenous flucloxacillin were enrolled in this prospective, observational, single-center pilot study. Patients treated with piperacillin/tazobactam or amoxicillin/clavulanic acid served as controls. Matrix-assisted laser desorption–ionization time-of-flight mass spectrometry measurements were performed to calculate the stoichiometry of the antibiotic/albumin complexes. In addition, the associations between the stoichiometry and antibiotic treatment duration, serum albumin concentration, or time since flucloxacillin treatment cessation were assessed using association plots. Results: Eleven patients treated with flucloxacillin and 4 control patients were enrolled. A total of 251 stoichiometric measurements were considered. Large intra- and interindividual differences were observed in the stoichiometry. These values ranged from 0 to 6 flucloxacillin molecules bound to albumin. In 8 patients (72%), an increase in the stoichiometry as the number of flucloxacillin treatment days increased was confirmed. In addition, the stoichiometry increased at low albumin concentrations, and a stoichiometry of ≥3 was observed for 2–8 days after flucloxacillin treatment cessation. Conclusions: Prolonged flucloxacillin treatment and low serum albumin concentrations were associated with a high stoichiometry of flucloxacillin/albumin complexes in hospitalized patients with serum hypoalbuminemia. This study illustrates that protein binding is not a constant, thereby contributing to current understanding of the pharmacokinetics, effectiveness, and toxicity of flucloxacillin.
- Open Access
- 17 December 2025
- Published by Elsevier in Psychiatry Research
- Vol. 356, 116913
Efficacy of glutamate-GABA modulator riluzole for the treatment of cognitive and psychotic symptoms in 22q11.2 deletion syndrome: A placebo-controlled crossover trial
- 17 December 2025
- Published by Elsevier in Psychiatry Research
- Vol. 356, 116913
Open AccessEfficacy of glutamate-GABA modulator riluzole for the treatment of cognitive and psychotic symptoms in 22q11.2 deletion syndrome: A placebo-controlled crossover trial
- Open Access
- 12 November 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (1) , 185-187
The association between unbound ceftriaxone area under the curve in the first 24 treatment hours and longitudinal C-reactive protein response in critically ill patients: an observational study
- 12 November 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (1) , 185-187
Open AccessThe association between unbound ceftriaxone area under the curve in the first 24 treatment hours and longitudinal C-reactive protein response in critically ill patients: an observational study
- Open Access
- 22 June 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (9) , 2755-2761
Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
Cefuroxime is a second‐generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear. We performed an observational PK study in ICU patients. The objective of this study was to gain knowledge on the PK of cefuroxime and investigate target attainment of currently clinically applied dosing regimens. To identify the most suitable regimen the time above the minimal inhibitory concentration of the unbound drug (%fT > MIC) was calculated for different minimal inhibitory concentrations (MICs) and estimated Glomerular Filtration rates (eGFRs). Twenty patients were included with an average age of 66 years and modification of diet in renal disease (MDRD) (not indexed by BSA) of 90 [60–117.5] mL/min. A two‐compartment model best fitted the data, with eGFR as a covariate. Probability of target attainment (PTA) was 43% for a 1500‐mg q8h bolus dosage for the EUCAST break point of 8 mg/L for a typical individual with a eGFR of 60 mL/min. Dosing continuously using 4.5 g/day obtained 100% PTA for a typical individual with a eGFR up to 120 mL/min.
- 22 June 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (9) , 2755-2761
Open AccessPopulation pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
Cefuroxime is a second‐generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear. We performed an observational PK study in ICU patients. The objective of this study was to gain knowledge on the PK of cefuroxime and investigate target attainment of currently clinically applied dosing regimens. To identify the most suitable regimen the time above the minimal inhibitory concentration of the unbound drug (%fT > MIC) was calculated for different minimal inhibitory concentrations (MICs) and estimated Glomerular Filtration rates (eGFRs). Twenty patients were included with an average age of 66 years and modification of diet in renal disease (MDRD) (not indexed by BSA) of 90 [60–117.5] mL/min. A two‐compartment model best fitted the data, with eGFR as a covariate. Probability of target attainment (PTA) was 43% for a 1500‐mg q8h bolus dosage for the EUCAST break point of 8 mg/L for a typical individual with a eGFR of 60 mL/min. Dosing continuously using 4.5 g/day obtained 100% PTA for a typical individual with a eGFR up to 120 mL/min.
- 29 December 2024
- Published by Springer Nature
- p. 295-307
Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information
- 29 December 2024
- Published by Springer Nature
- p. 295-307
Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information
- Open Access
- 21 July 2024
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 12 (4) , 638-651
Possible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review
Introduction: Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However, findings from genetic association and pharmacotherapeutic studies have been inconsistent. Objectives: To provide a quality overview of neurobiological targets that are potentially associated with LPE by investigating genetic association and pharmacotherapeutic studies. Methods: This scoping review was conducted per the PRISMA-ScR tool (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Five databases were searched in March 2023 without timeline- or language-related restrictions. Results: After deduplication, 3949 records were obtained for review. Following screening and full-text review with citation tracking, 52 studies were included: 18 genetic and 34 pharmacotherapy studies. Serotonergic targets, such as the serotonin transporter and pre- and postsynaptic serotonergic receptors, were most often associated with LPE in genetic and pharmacotherapeutic studies. Mixed results were found among polymorphisms within genetic studies. This mechanism is in accordance with pharmacotherapeutic studies, as the highest efficacy was found for potent serotonergic antidepressants. Successful treatment was also observed with medication acting on phosphodiesterase-5 enzyme, such as tadalafil and vardenafil. Analyses of other genetic association studies did not yield any further evidence for associated targets. Conclusions: This review is the first comprehensive scoping review on LPE. We found that serotonergic targets are most often associated with LPE, suggesting that the serotonergic pathway is a predisposing factor in LPE. Furthermore, there is some evidence for phosphodiesterase 5 inhibitors, which should be investigated. Other previously investigated neurobiological targets appear less likely to contribute to LPE. Future studies should focus on multiple targets, ideally in a genome-wide association study design. This review has been registered with the Open Science Framework (doi:10.17605/OSF.IO/JUQSD).
- 21 July 2024
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 12 (4) , 638-651
Open AccessPossible pathophysiologic roles of neurotransmitter systems in men with lifelong premature ejaculation: a scoping review
Introduction: Lifelong premature ejaculation (LPE) is a subtype of premature ejaculation. Genetic research on LPE has primarily focused on neurotransmitters such as serotonin, dopamine, and norepinephrine, whereas LPE treatment studies have focused on drugs such as selective serotonin reuptake inhibitors. However, findings from genetic association and pharmacotherapeutic studies have been inconsistent. Objectives: To provide a quality overview of neurobiological targets that are potentially associated with LPE by investigating genetic association and pharmacotherapeutic studies. Methods: This scoping review was conducted per the PRISMA-ScR tool (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Five databases were searched in March 2023 without timeline- or language-related restrictions. Results: After deduplication, 3949 records were obtained for review. Following screening and full-text review with citation tracking, 52 studies were included: 18 genetic and 34 pharmacotherapy studies. Serotonergic targets, such as the serotonin transporter and pre- and postsynaptic serotonergic receptors, were most often associated with LPE in genetic and pharmacotherapeutic studies. Mixed results were found among polymorphisms within genetic studies. This mechanism is in accordance with pharmacotherapeutic studies, as the highest efficacy was found for potent serotonergic antidepressants. Successful treatment was also observed with medication acting on phosphodiesterase-5 enzyme, such as tadalafil and vardenafil. Analyses of other genetic association studies did not yield any further evidence for associated targets. Conclusions: This review is the first comprehensive scoping review on LPE. We found that serotonergic targets are most often associated with LPE, suggesting that the serotonergic pathway is a predisposing factor in LPE. Furthermore, there is some evidence for phosphodiesterase 5 inhibitors, which should be investigated. Other previously investigated neurobiological targets appear less likely to contribute to LPE. Future studies should focus on multiple targets, ideally in a genome-wide association study design. This review has been registered with the Open Science Framework (doi:10.17605/OSF.IO/JUQSD).
- 4 December 2023
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 21 (2) , 122-128
The rs6296 polymorphism in the 5-HT1b receptor in Dutch men with lifelong premature ejaculation: a genetic case-control association study
Lifelong premature ejaculation (LPE) is a rare sexual condition believed to be caused by genetic neurobiological disorders. In this study we sought to evaluate the genetic association between the rs6296 polymorphism of the 5-HT1b receptor and intravaginal ejaculation latency times (IELTs) in men with LPE compared with men in a control group. This study was a prospective observational genetic case-control association study. The LPE definition of the International Society for Sexual Medicine (ISSM) 2013 was used. Patients were recruited in 2005-2009 while attending the department of Neurosexology, HagaZiekenhuis, the Netherlands. We obtained IELTs with the stopwatch method. Polymerase chain reaction (PCR) was used for genotyping rs6296. A randomly selected group of European Caucasian men from the 1000GENOMES project was used as a control group. Study outcomes included results of comparisons of analysis of variance (ANOVA) tests between genotypes and IELTs in study participants, genotypes of cases and controls determined with the chi-square test, and expressions of allelotype- and genotype-specific risks for LPE determined with odds ratios. In total, 67 men with LPE were included in this study. The geometric mean (SD) IELT was 32.0 (27.4) seconds and was non-normally distributed. Genotype frequencies consisted of 29 (43.3%) GG, 31 (46.3%) GC, and 7(10.4%) CC individuals in the LPE group. Log-transformed IELTs were not statistically significant (per ANOVA tests) in men with GG, GC, or CC genotypes (P = .54). Genotype frequencies consisted of 16 (6.6%) GG; 93 (38.8%) GC, and 131 (54.6%) CC individuals in the control group (n = 240). Significant differences were found when comparing allele (P = 1.02e-17) and genotype (P = 3.22e-16) frequencies in cases and controls using a chi-square test. A statistically significant increased risk for LPE was found for carriers of the G allele (OR 5.62; 95% CI 4.13-9.42). Statistically significant risks were also found for the CG genotype (OR 6.24; 95% CI 2.63-14.77) and the GG genotype (OR 33.92; 95% CI 12.79-89.93). By investigating polymorphisms in target genes the neuro-pathophysiology of LPE could be further elaborated, potentially leading to more effective treatment. This is to our knowledge the first study investigating rs6296 with regard to LPE. By using a strict definition for LPE (ISSM 2013) and using the stopwatch method for measuring IELTs, bias in selection of true LPE patients will be relatively low. This study is limited by a relatively small study population and the lack of IELT data in the control group. This study shows a genetic association in rs6296 in men with LPE compared with healthy controls. This result warrants attempted replication in future studies.
- 4 December 2023
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 21 (2) , 122-128
The rs6296 polymorphism in the 5-HT1b receptor in Dutch men with lifelong premature ejaculation: a genetic case-control association study
Lifelong premature ejaculation (LPE) is a rare sexual condition believed to be caused by genetic neurobiological disorders. In this study we sought to evaluate the genetic association between the rs6296 polymorphism of the 5-HT1b receptor and intravaginal ejaculation latency times (IELTs) in men with LPE compared with men in a control group. This study was a prospective observational genetic case-control association study. The LPE definition of the International Society for Sexual Medicine (ISSM) 2013 was used. Patients were recruited in 2005-2009 while attending the department of Neurosexology, HagaZiekenhuis, the Netherlands. We obtained IELTs with the stopwatch method. Polymerase chain reaction (PCR) was used for genotyping rs6296. A randomly selected group of European Caucasian men from the 1000GENOMES project was used as a control group. Study outcomes included results of comparisons of analysis of variance (ANOVA) tests between genotypes and IELTs in study participants, genotypes of cases and controls determined with the chi-square test, and expressions of allelotype- and genotype-specific risks for LPE determined with odds ratios. In total, 67 men with LPE were included in this study. The geometric mean (SD) IELT was 32.0 (27.4) seconds and was non-normally distributed. Genotype frequencies consisted of 29 (43.3%) GG, 31 (46.3%) GC, and 7(10.4%) CC individuals in the LPE group. Log-transformed IELTs were not statistically significant (per ANOVA tests) in men with GG, GC, or CC genotypes (P = .54). Genotype frequencies consisted of 16 (6.6%) GG; 93 (38.8%) GC, and 131 (54.6%) CC individuals in the control group (n = 240). Significant differences were found when comparing allele (P = 1.02e-17) and genotype (P = 3.22e-16) frequencies in cases and controls using a chi-square test. A statistically significant increased risk for LPE was found for carriers of the G allele (OR 5.62; 95% CI 4.13-9.42). Statistically significant risks were also found for the CG genotype (OR 6.24; 95% CI 2.63-14.77) and the GG genotype (OR 33.92; 95% CI 12.79-89.93). By investigating polymorphisms in target genes the neuro-pathophysiology of LPE could be further elaborated, potentially leading to more effective treatment. This is to our knowledge the first study investigating rs6296 with regard to LPE. By using a strict definition for LPE (ISSM 2013) and using the stopwatch method for measuring IELTs, bias in selection of true LPE patients will be relatively low. This study is limited by a relatively small study population and the lack of IELT data in the control group. This study shows a genetic association in rs6296 in men with LPE compared with healthy controls. This result warrants attempted replication in future studies.